{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:13:24Z","timestamp":1790097204233,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002726","name":"Beijing Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7191009"],"award-info":[{"award-number":["7191009"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7204293"],"award-info":[{"award-number":["7204293"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["NCC2019Q-038"],"award-info":[{"award-number":["NCC2019Q-038"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011176","name":"Peking Union Medical College","doi-asserted-by":"publisher","award":["3332019053"],"award-info":[{"award-number":["3332019053"]}],"id":[{"id":"10.13039\/501100011176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872160"],"award-info":[{"award-number":["81872160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.intimp.2020.107186","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T22:52:19Z","timestamp":1606949539000},"page":"107186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor"],"prefix":"10.1016","volume":"90","author":[{"given":"Qiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.107186_b0005","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","author":"Greene","year":"2002","journal-title":"AJCC Cancer Staging Manual"},{"issue":"3","key":"10.1016\/j.intimp.2020.107186_b0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.intimp.2020.107186_b0015","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA: A Cancer J. Clinicians"},{"issue":"3","key":"10.1016\/j.intimp.2020.107186_b0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"334","key":"10.1016\/j.intimp.2020.107186_b0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad3001","article-title":"Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence","volume":"8","author":"Balko","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2009.02.010","article-title":"Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications","volume":"284","author":"Panani","year":"2009","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12185-013-1480-z","article-title":"Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation","volume":"99","author":"Xu","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.intimp.2020.107186_b0045","doi-asserted-by":"crossref","unstructured":"A B, R A, H B, I K, V R, U M, M M, T R, M B-A: JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22(6):796-811.","DOI":"10.1016\/j.ccr.2012.10.023"},{"key":"10.1016\/j.intimp.2020.107186_b0050","doi-asserted-by":"crossref","unstructured":"LL M, V A, A M, M S, J S, SR W, N B-Q, JJ K, SA C, R M et al., The JAK2\/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121(7):2723\u20132735.","DOI":"10.1172\/JCI44745"},{"key":"10.1016\/j.intimp.2020.107186_b0055","doi-asserted-by":"crossref","unstructured":"ZC H, GM P, P dH, A T, J H, N P, Y Z, A M, SG H, GB M, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013, 73(11):3470\u20133480.","DOI":"10.1158\/0008-5472.CAN-12-4524-T"},{"key":"10.1016\/j.intimp.2020.107186_b0060","doi-asserted-by":"crossref","unstructured":"CP M, JD T, AN K, CM C, WY C, TH OY, D A, JD B, ND U, CA B: JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunology Res. 2014, 2(4):301-306.","DOI":"10.1158\/2326-6066.CIR-13-0189"},{"issue":"14","key":"10.1016\/j.intimp.2020.107186_b0065","first-page":"2515","article-title":"GDCRNATools: an R\/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC","volume":"34","author":"Li","year":"2018","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0070","first-page":"139","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"7","key":"10.1016\/j.intimp.2020.107186_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.intimp.2020.107186_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"issue":"7403","key":"10.1016\/j.intimp.2020.107186_b0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0090","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","article-title":"Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets","volume":"8","author":"Nagy","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.107186_b0095","first-page":"1","article-title":"survminer: Drawing Survival Curves using'ggplot2'","volume":"03","author":"Kassambara","year":"2017","journal-title":"R package version"},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1755-8794-2-18","article-title":"PrognoScan: a new database for meta-analysis of the prognostic value of genes","volume":"2","author":"Mizuno","year":"2009","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.intimp.2020.107186_b0105","article-title":"The Gene Ontology (GO) database and informatics resource","volume":"32(suppl_1):D258\u2013D261","author":"Consortium GO","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2020.107186_b0110","series-title":"Novartis Foundation Symposium: 2002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/0470857897.ch8","article-title":"The KEGG database","author":"Kanehisa","year":"2002"},{"issue":"21","key":"10.1016\/j.intimp.2020.107186_b0115","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.intimp.2020.107186_b0120","first-page":"4200","article-title":"TISIDB: an integrated repository portal for tumor\u2013immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.intimp.2020.107186_b0130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1382792","article-title":"PD-1 related transcriptome profile and clinical outcome in diffuse gliomas","volume":"7","author":"Liu","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2020.107186_b0135","first-page":"1","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.intimp.2020.107186_b0140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.sjbs.2019.08.002","article-title":"Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients","volume":"26","author":"Karim","year":"2019","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.intimp.2020.107186_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106012","article-title":"Breast cancer cells promote CD169(+) macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages","volume":"78","author":"Jing","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13058-018-0969-z","article-title":"Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions","volume":"20","author":"Johnston","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2020.107186_b0155","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/1535-7163.MCT-17-0667","article-title":"JAK2 inhibitor SAR302503 abrogates PD-L1 expression and targets therapy-resistant non-small cell lung cancers","volume":"17","author":"Pitroda","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"429","key":"10.1016\/j.intimp.2020.107186_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.intimp.2020.107186_b0165","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","article-title":"MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer","volume":"24","author":"Saigi","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2020.107186_b0170","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1016\/j.clbc.2018.05.006","article-title":"JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer","volume":"18","author":"Chen","year":"2018","journal-title":"Clin. Breast Cancer"},{"issue":"15","key":"10.1016\/j.intimp.2020.107186_b0175","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-16-2848","article-title":"Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma","volume":"23","author":"Giraldo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2020.107186_b0180","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijbiomac.2018.05.120","article-title":"Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms","volume":"116","author":"Wu","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"7414","key":"10.1016\/j.intimp.2020.107186_b0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2020.107186_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","article-title":"Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells","volume":"38","author":"Liang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2020.107186_b0195","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections","volume":"61","author":"Huang","year":"2018","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2020.107186_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24122338","article-title":"Piperlongumine induces apoptosis and synergizes with doxorubicin by inhibiting the JAK2-STAT3 pathway in triple-negative breast cancer","volume":"24","author":"Chen","year":"2019","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.intimp.2020.107186_b0205","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1172\/JCI91553","article-title":"JAK2-binding long noncoding RNA promotes breast cancer brain metastasis","volume":"127","author":"Wang","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2020.107186_b0210","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920336535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920336535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:43:59Z","timestamp":1762551839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920336535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"alternative-id":["S1567576920336535"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107186","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107186"}}